Screening for prostate cancer: have you had your cholesterol measured?
Screening for prostate cancer has become one of the most common topics of conversation at urological oncology meetings. Most people have a bias as to whether there should or should not be a national screening programme. Unfortunately there are many unanswered questions, which may or may not be possible to answer definitively. In a balanced and scholarly review of the subject, Professor Peter Boyle indicates several flaws in the agreement for screening, but feels that PSA testing will continue unabated. The authors from the University of Stellenbosch review the plentiful literature relating to testicular torsion and functional recovery. They also review the mechanism of injury and the effect on the contralateral testis.
Boyle
P
P
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
D017677:Age Distribution; D002784:Cholesterol / Q000097:blood; D005544:Forecasting; D006293:Health Promotion; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods* / Q000592:standards; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000401:mortality / Q000517:prevention & control*; D011878:Radiotherapy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012680:Sensitivity and Specificity; D015996:Survival Rate
D002784:Cholesterol; D017430:Prostate-Specific Antigen